Our Blog

​Get to know our progress!

September 13, 2018

Get to know our progress!
 
At Ability Pharma we are very proud of all the progress we have done and we are continuously doing in the development of ABTL0812.
 
Today we would like to explain our evolution since the last financing round we had in 2016. Only 2 years have gone by but our progress has been enormous.
 
Our progress in 2016
 
In 2016 our last financing round was carried out and with this we achieved very important milestones such as the license agreement with SciClone Pharmaceuticals to develop, promote, market, distribute and sell ABTL0812 in China, as well as in Hong Kong, Macao, Taiwan and Vietnam.
 
In addition, the prestigious medical journal Clinical Cancer Research published the novel mechanism of action of our drug ABTL0812 in its publication.
 
Regarding the clinical development, in December 2016, the phase 1/2b clinical trial started at the Institut Vall d'Hebron d’Oncología (VHIO, Barcelona) and the Institut Català d’Oncología (ICO, Hospitalet, Badalona y Girona). The study included later the INCLIVA (Valencia), the Institut Gustave Roussy (Paris), the Centre Léon-Bérard (Lyon), the Institut Paoli-Calmettes (Marselle) and the Hospital Universitario Virgen del Rocío (Seville).
 
Our progress in 2017
 

Last year, was an important year for our company and our drug, achieving significant milestones.
 
The US-FDA approved the phase 1/2a clinical trial with ABTL0812, in patients with endometrial cancer or squamous non-small cell lung cancer, in combination with paclitaxel and carboplatin as first-line therapy line, which validated the ongoing clinical trial in Europe.
 
In August of that year, the EMA granted the ODD (Orphan Drug Designation) to ABTL0812 for pancreatic cancer, also previously granted by the FDA in November 2016.
 
In December 2017 we presented the amendment to the IND in the FDA to conduct an open phase 1/2b study to evaluate the efficacy and safety of ABTL0812 in combination with gemcitabine and nab-paclitaxel in patients with advanced metastatic pancreatic cancer as first-line therapy and as maintenance after chemotherapy.

Present and future
 
In January of 2018, only one month after its presentation, the protocol for the phase 1/2 clinical trial with ABTL0812 in patients with pancreatic cancer was approved by the FDA.
 
 
Font: Expansión (Catalunya) 20/02/2018
 
We are currently submerged in phase 2 clinical trial to treat endometrial cancer and lung cancer in 80 patients in centers of Spain and France.
 
Our future is ambitious, we want to stop cancer from being a deadly disease and turn it into a chronic illness. To do this, we have just started a new fundraising campaign through a crowdfunding.
 
The primary objective with our crowdfunding campaign is to achieve 1 million euros in order to complete the phase 1/2 study with the development of additional biomarkers and the development of a new formulation. A successful outcome of the second trial would put us in a strong position to negotiate a licensing agreement to a big pharma or would allow an IPO in a stock market.
 
Would you like to know more about our project? Do not hesitate to send us an email to the following address: contact@abilitypharma.com
 

LATEST NEWS

19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017

News

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
15.12.2016

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG